ATTACHMENT II__DAF ACT CSO_COVID-19 Response.pdf

ATTACHMENT II – DAF ACT CSO FA811921SC001

ATTACHMENT II

PROSPECTIVE EFFORT DESCRIPTIONS

The paragraphs below represent potential Areas of Interest (AoI)s (in no particular order) being contemplated for execution under the DAF ACT COVID-19 Commercial Solutions Opening.

There is NO requirement for perspective offerors to provide any response to the information being provided below. Neither of these efforts are guaranteed to post and therefore all interested parties must check back here at the Government point of entry for actual posting(s). The below is for information only and is not intended to solicit any effort or response. Any effort put forth by a potential offeror is taken at NO cost to the Government. As stated in the DAF ACT COVID-19

CSO at para 3.2, funds are not presently available for efforts under this CSO. The Government’s obligation under this CSO is contingent upon the availability of appropriated funds from which payment for AoI purposes can be made. No legal liability on the part of the Government for any payment may arise until funds are made available to the Contracting Officer for subsequent AOIs until the Contractor receives notice of such availability, which will be confirmed in writing by the

Contracting Officer. The CSO is not limited to the following prospective efforts.

EFFORT: Rapid Point of Care Testing

Significantly increasing the U.S. access to accurate, easy-to-use, point of care (POC) technologies with potential for in-home use will be critical to getting Americans back to work safely. These technologies can also serve as platforms for responding to future pandemics and managing ongoing medical challenges (e.g. influenza).

Given the technological, regulatory, and execution challenges at hand, we have established a collaboration between the Department of Health and Human Services (HHS) (Office of the

Assistant Secretary, Biomedical Advanced Research and Development Authority (BARDA), National Institute of Health (NIH)), and the United States Air Force (USAF) to understand the industry’s ability to rapidly mature and scale POC testing technology with the potential for in-home use. This could include molecular, antigen, or any other underlying methodology for SARS-

CoV2 detection, provided it passes regulatory review.

EFFORT: Multimodal transport SARS-CoV Testing Laboratory Area of Interest (AoI)

Executive Summary

Throughout the Air Force, a lack of mobile Severe Acute Respiratory Syndrome Coronavirus 2

(SARS COV-2) testing platforms has led to a gap in on-site, rapid response testing capabilities in locations not supported by a traditional laboratory. The United States Air Force (USAF) is seeking a capability that consists of a multimodal transport SARS-CoV-2 testing laboratory system(s) for ground operations, configured for land, sea, and air (multi-modal) transport. This lab shall be

Clinical Laboratory Improvement Amendment (CLIA) compliant, be able to operate globally in any region, and any condition in which local laboratory support is not available. The lab shall be composed of all items necessary to perform sample collection, testing, and resulting of 200 or

ATTACHMENT II – DAF ACT CSO FA811921SC001

more SARS‐CoV‐2 Polymerase Chain Reaction (PCR) tests per 24 hours. An initial quantity of three (3) labs are being sought for evaluation. As an option, up to five (5) additional labs may be procured after evaluation. To supplement this lab, the USAF is also seeking five (5) man-portable systems to extend testing capabilities into even more austere conditions for evaluation. As an option, up to fifteen (15) additional labs may be procured after evaluation.

EFFORT: Supply Chain: COVID-19 Diagnostics Testing

This effort may transpire to address supply chain gaps related to all areas of diagnostics from vendors with U.S. based operations who believe they can meet Health and Human Services

Assistant Secretary for Health priorities for expanding and diversifying supply of critical materials and equipment related to COVID diagnostics, including, but not limited to sample collection consumables, resins (plastics), nitrocellulose membrane, pipette tips, automation that support diagnostics, and equipment that support manufacturing of diagnostics-related materials.

EFFORT: Glove Industrial Base Expansion

The recent COVID-19 Public Health Emergency has illuminated the importance of increasing the

United States’ domestic capacity to manufacture medical gloves and glove making material and equipment. The intent of this AoI is to understand the industry’s ability to increase domestic manufacturing capacity. The country’s ability to increase domestic manufacturing capacity is critical to not only respond to the pandemic but also to ensure the security of glove manufacturing within the US.

The Department of Defense Joint Rapid Acquisition Cell (JRAC), Defense Assisted Acquisition

(DA2) team and Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT) need to understand industry’s ability to increase domestic manufacturing of non-sterile, powder-free, patient examination gloves and/or acryloNitrile Butadiene Rubber (NBR) raw glove manufacturing material and/or the machinery required to produce gloves.